NCL Technology Ventures

Ampersand Health is focused on developing digital therapeutics for individuals with long-term inflammatory conditions. Based in London and incorporated in 2014, the company offers a comprehensive digital platform that includes the Ampersand Healthsuite, a management tool designed for patients, and Healthsuite for Clinicians, which supports clinician-led, patient-centered self-management. The platform utilizes behavioral science to deliver personalized therapy, featuring expert-led courses, self-management tracking, and clinical messaging. Ampersand Health aims to enhance patients' mental health and quality of life while also providing significant cost savings for healthcare providers by reducing overall healthcare utilization.

Curesponse is a diagnostics company based in Tel Aviv-Yafo, Israel, founded in 2017. It specializes in developing a three-dimensional tissue culture system that models cancer growth and drug response. The company's innovative platform allows patients and clinicians to send tumor samples for testing, preserving the cancer tissue's architecture, including its vasculature and immune system. This accurate reflection of cancer growth enables healthcare providers to make more informed decisions about drug therapies tailored to individual patients. By moving beyond traditional genomic predictions to functional responses in living patient cells, Curesponse aims to enhance personalized cancer medicine, improve survival rates, and reduce unnecessary medical interventions.

Ampersand Health is focused on developing digital therapeutics for individuals with long-term inflammatory conditions. Based in London and incorporated in 2014, the company offers a comprehensive digital platform that includes the Ampersand Healthsuite, a management tool designed for patients, and Healthsuite for Clinicians, which supports clinician-led, patient-centered self-management. The platform utilizes behavioral science to deliver personalized therapy, featuring expert-led courses, self-management tracking, and clinical messaging. Ampersand Health aims to enhance patients' mental health and quality of life while also providing significant cost savings for healthcare providers by reducing overall healthcare utilization.

Emteq creates facial wearables - glasses - that understand the expressions and emotions of the wearer, enabling improved Human-Computer Interaction, Human Augmentation and Emotion Analytics through advanced AI techniques. Emteq was founded by Graeme Cox and Charles Nduka in 2015 and is headquartered in Brighton, East Sussex.

Azadyne’s novel approach to treating autoimmune disease focuses on an unexplored pathway in the body and is based on research conducted at Trinity by Associate Professor in Biochemistry Vincent Kelly, Professor of Synthetic Chemistry Professor Stephen Connon and assistant Professor in Chemistry John Michael Southern.

Revolo Biotherapeutics specializes in developing innovative therapies aimed at treating autoimmune and allergic diseases by resetting the immune system for long-term disease remission. Founded in 2011 and previously known as Immune Regulation, the company focuses on creating anti-inflammatory peptides that offer significant advancements in the management of moderate to severe chronic inflammatory conditions. These peptides have the potential to modify disease progression and promote remission, providing improved treatment options for patients suffering from conditions such as asthma, atopic dermatitis, and inflammatory bowel diseases. By achieving effective long-term outcomes with less frequent dosing and without suppressing the immune system, Revolo Biotherapeutics aims to transform the landscape of immuno-inflammatory disease treatment.

Sana Health, Inc. is a digital health company specializing in a bio-therapeutic device aimed at fostering relaxation to alleviate pain and tension. The company has developed a non-addictive mask and headphone system that employs audio-visual stimulation to enhance the balance between the brain's left and right hemispheres, facilitating a deep state of meditation. This innovative device uses coordinated pulses of light and sound to guide users into a restorative state, thereby improving mental well-being and addressing chronic pain and insomnia. In addition to the hardware, Sana Health offers a mobile application available on both the App Store and Google Play, allowing users to access its features conveniently. Founded in 2015 and headquartered in Lafayette, Colorado, with an additional office in Mill Valley, California, Sana Health is involved in pivotal studies concerning its technology's applications for conditions such as fibromyalgia and neuropathic pain, as well as trials focusing on anxiety and PTSD.

Andiamo is a digital clinic focused on providing specialized care for neuromuscular conditions, starting with cerebral palsy. The company offers a custom medical wearables platform that allows families to connect with specialists conveniently and efficiently. By leveraging technology, Andiamo aims to improve access to healthcare resources and support for those affected by neuromuscular disorders, ensuring that families receive the necessary care when and where they need it.

Peptinnovate Ltd is a drug development company based in Stevenage, United Kingdom, focused on researching and developing immune regulating therapies for asthma and various immuno-inflammatory diseases, including atopic dermatitis and inflammatory bowel disease. Founded in 2011, the company leverages a unique biotechnology inspired by the mechanisms employed by Mycobacterium tuberculosis to evade the host immune system and modulate inflammatory responses. Through its innovative approach, Peptinnovate aims to address unmet medical needs in the treatment of these chronic conditions.

Coomtech Ltd. is a sustainable energy technology company based in Sandwich, United Kingdom, founded in 2011. The company specializes in developing innovative technologies for drying and upgrading coal and biomass. Its surface moisture removal technology uses high-velocity, low-pressure air to eliminate moisture from coal particles, while its inherent moisture removal technology employs hydrothermal treatment to displace internal moisture through chemical reactions. These processes enhance combustion efficiency, significantly reducing energy costs and CO2 emissions in the construction and renewable energy sectors. Coomtech collaborates with various strategic partners, including Narec Capital Ltd. and the University of Greenwich Wolfson Centre, to advance its technology and support bulk material industries in improving plant efficiency and sustainability.

TC BioPharm Limited is a clinical development company based in Edinburgh, United Kingdom, that focuses on the development, manufacture, and commercialization of innovative cell-based therapies for cancer and severe viral infections. The company's flagship product, ImmuniCell, is an autologous therapy that involves the expansion of patient-derived cells in cleanroom environments to create treatments for various tumor types and viral infections. TC BioPharm is advancing its research through Phase II/III clinical studies targeting renal cell carcinoma, non-small cell lung cancer, and melanoma. The company utilizes its proprietary allogeneic gamma delta T cell platform to create novel immunotherapy products aimed at improving patient health and quality of life. Additionally, TC BioPharm has formed strategic partnerships with Medinet, bluebird bio, and NIPRO Corporation to enhance its development capabilities. Founded in 2013, the company is committed to providing safer, more cost-effective, and durable therapies for patients in need.

Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at treating life-threatening diseases. The company employs its proprietary Alphamer technology, which utilizes chemically synthesized molecules to redirect naturally occurring antibodies towards specific pathogens, enhancing the body's immune response to fight infections. Centauri's approach features a dual mechanism of action: a moiety that directly targets cell surface antigens and a glycan effector domain that activates a robust pre-existing polyclonal immune response. This response facilitates cell death through mechanisms such as complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has produced promising pre-clinical data, showcasing significant enhancements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, along with in vivo proof of concept data across multiple infection models.